Molecular Formula | C22H24N2O2 |
Molar Mass | 348.43816 |
Solubility | H2O: soluble5mg/mL (clear solution) |
Appearance | powder |
Color | white to beige |
Storage Condition | room temp |
In vitro study | NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor. SKOV-3 cells with long-term exposure of 1 μM NSC23925 show stable growth in culture medium. NSC23925 specifically inhibits Pgp overexpression to prevent the emergence of paclitaxel resistance during paclitaxel treatment. NSC23925 reverses chemoresistance in a wide variety of tumor types where Multidrug resistance 1 (MDR1) is highly expressed. Maximal reversal of MDR is typically seen in NSC23925 doses between 0.5 and 1 µM. The IC 50 for NSC23925 is 8 µM in SKOV-3/SKOV-3 TR and 25 µM in OVCAR8/OVCAR8 TR cell lines, whereas the mean concentration of NSC23925 required for maximal reversal of resistance in SKOV-3 TR or OVCAR8 TR to cytotoxic drugs is 0.5 µM to 1 µM. |
In vivo study | Both saline alone and NSC23925 alone treated tumors grow progressively. The usage of NSC23925 in paclitaxel chemotherapy significantly prolongs anticancer efficacy of paclitaxel. |
Hazard Symbols | T - Toxic |
Risk Codes | 25 - Toxic if swallowed |
Safety Description | 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 2811 6.1 / PGIII |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.87 ml | 14.35 ml | 28.699 ml |
5 mM | 0.574 ml | 2.87 ml | 5.74 ml |
10 mM | 0.287 ml | 1.435 ml | 2.87 ml |
5 mM | 0.057 ml | 0.287 ml | 0.574 ml |
biological activity | NSC23925 is a novel, selective and potent P-glycoprotein (Pgp) inhibitor. |
Target | P-glycoprotein |